Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: A multicenter retrospective cohort study
Authors: Mahmoud Sherif Hanafy , Hefny Fatma R. , Panos Nicholas G. , Delucilla Laura , Ngan Zinquon , Perreault Marc M. , Hamilton Leslie A. , Rowe A. Shaun , Buschur Pamela L. , Owusu‐Guha Jocelyn , Almohaish Sulaiman , Sandler Melissa , Armahizer Michael J. , Barra Megan E. , Cook Aaron M. , Barthol Colleen A. , Hintze Trager D. , Cantin Anna , Traeger Jessica , Blunck Joseph R. , Shewmaker Justin , Burgess Sarah V. , Kaupp Kristin , Brown Caitlin S. , Clark Sarah L. , Wieruszewski Erin D. , Tesoro Eljim P. , Ammar Abdalla A. , Ammar Mahmoud A. , Binning Mandy J. , Naydin Stanislav , Fox Neal , Peters David M. , Mahmoud Leana N. , Keegan Shaun P. , Brophy Gretchen M. 
Published: March 2023

AbstractBackgroundNimodipine improves outcomes following aneurysmal subarachnoid hemorrhage (aSAH) and current guidelines suggest that patients with aSAH receive nimodipine for 21 days. Patients with no difficulty swallowing will swallow the whole capsules or tablets; otherwise, nimodipine liquid must be drawn from capsules, tablets need to be crushed, or the commercially available liquid product be used to facilitate administration through an enteral feeding tube (FT). It is not clear whether these techniques are equivalent. The goal of the study was to determine if different nimodipine formulations and administration techniques were associated with the safety and effectiveness of nimodipine in aSAH.MethodsThis was a retrospective multicenter observational cohort study conducted in 21 hospitals across North America. Patients admitted with aSAH and received nimodipine by FT for ≥3 days were included. Patient demographics, disease severity, nimodipine administration, and study outcomes were collected. Safety end points included the prevalence of diarrhea and nimodipine dose reduction or discontinuation secondary to blood pressure reduction. Predictors of the study outcomes were analyzed using regression modeling.ResultsA total of 727 patients were included. Administration of nimodipine liquid product was independently associated with higher prevalence of diarrhea compared to other administration techniques/formulations (Odds ratio [OR] 2.28, 95% confidence interval [CI] 1.41–3.67, p‐value = 0.001, OR 2.76, 95% CI 1.37–5.55, p‐value = 0.005, for old and new commercially available formulations, respectively). Bedside withdrawal of liquid from nimodipine capsules prior to administration was significantly associated with higher prevalence of nimodipine dose reduction or discontinuation secondary to hypotension (OR 2.82, 95% CI 1.57–5.06, p‐value = 0.001). Tablet crushing and bedside withdrawal of liquid from capsules prior to administration were associated with increased odds of delayed cerebral ischemia (OR 6.66, 95% CI 3.48–12.74, p‐value <0.0001 and OR 3.92, 95% CI 2.05–7.52, p‐value <0.0001, respectively).ConclusionsOur findings suggest that enteral nimodipine formulations and administration techniques might not be equivalent. This could be attributed to excipient differences, inconsistency and inaccuracy in medication administration, and altered nimodipine bioavailability. Further studies are needed.